Intech Investment Management LLC purchased a new position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,387 shares of the company's stock, valued at approximately $462,000.
A number of other institutional investors and hedge funds have also made changes to their positions in PRVA. Nisa Investment Advisors LLC raised its stake in Privia Health Group by 107.5% during the second quarter. Nisa Investment Advisors LLC now owns 1,795 shares of the company's stock worth $31,000 after purchasing an additional 930 shares during the period. Louisiana State Employees Retirement System raised its position in Privia Health Group by 2.6% in the 2nd quarter. Louisiana State Employees Retirement System now owns 52,200 shares of the company's stock valued at $907,000 after purchasing an additional 1,300 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Privia Health Group by 8.8% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 9,758 shares of the company's stock worth $170,000 after acquiring an additional 788 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Privia Health Group by 7.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,742 shares of the company's stock worth $413,000 after buying an additional 1,653 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its holdings in shares of Privia Health Group by 11.5% in the second quarter. Peregrine Capital Management LLC now owns 314,190 shares of the company's stock valued at $5,461,000 after acquiring an additional 32,311 shares during the period. 94.48% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Privia Health Group
In other news, CEO Parth Mehrotra sold 135,142 shares of Privia Health Group stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $18.50, for a total value of $2,500,127.00. Following the completion of the transaction, the chief executive officer now owns 247,771 shares in the company, valued at approximately $4,583,763.50. This trade represents a 35.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.20% of the stock is currently owned by corporate insiders.
Privia Health Group Price Performance
Privia Health Group stock traded down $0.65 during midday trading on Tuesday, hitting $21.66. 447,431 shares of the company were exchanged, compared to its average volume of 851,362. The company's fifty day moving average price is $19.31 and its 200-day moving average price is $18.74. The company has a market cap of $2.60 billion, a PE ratio of 216.62, a price-to-earnings-growth ratio of 5.61 and a beta of 0.83. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $24.30.
Analyst Ratings Changes
A number of equities analysts have recently commented on PRVA shares. Truist Financial lifted their target price on shares of Privia Health Group from $24.00 to $27.00 and gave the company a "buy" rating in a report on Friday, November 8th. KeyCorp initiated coverage on shares of Privia Health Group in a research note on Friday, October 11th. They set an "overweight" rating and a $23.00 target price for the company. Barclays increased their price objective on Privia Health Group from $19.00 to $21.00 and gave the stock an "equal weight" rating in a research report on Friday, November 8th. Robert W. Baird lifted their price target on Privia Health Group from $23.00 to $24.00 and gave the company an "outperform" rating in a research note on Monday, August 26th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $24.93.
Check Out Our Latest Research Report on Privia Health Group
Privia Health Group Profile
(
Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Further Reading
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
